|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.06 USD | -1.10% |
|
+7.88% | +40.13% |
| 07-22 | Celldex Therapeutics, Inc. - Special Call | |
| 07-22 | Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -1.10% | +7.88% | -0.81% | +17.80% | +40.13% | +71.52% | +10.54% | -12.91% | -44.23% | 2.99B | |
| +0.84% | +1.72% | -0.91% | +18.74% | +5.80% | +0.60% | +16.12% | -20.91% | +212.47% | 48.53B | |
| -2.41% | -0.90% | -0.90% | +34.45% | +135.44% | +411.96% | +472.09% | +539.16% | - | 39.87B | |
| -1.16% | +12.96% | +13.51% | +48.96% | +4.26% | +28.81% | +7.27% | -4.97% | +203.02% | 38.68B | |
| -1.88% | -3.03% | +6.17% | +7.54% | +4.02% | +5.69% | +66.52% | -3.48% | +1,128.65% | 35.13B | |
| -1.74% | +5.12% | +5.72% | -2.23% | +8.31% | +14.44% | +44.64% | -13.82% | +159.46% | 29.79B | |
| -0.21% | -4.04% | +3.50% | +38.22% | +2.75% | +36.40% | +126.06% | +228.73% | - | 16.11B | |
| -2.85% | -3.92% | -11.14% | +10.40% | - | - | - | - | - | 16.08B | |
| +0.12% | +1.97% | -1.61% | +17.94% | +9.36% | +2.55% | +15.90% | -33.29% | +82.12% | 13.61B | |
| -1.19% | -1.32% | -5.49% | +44.94% | -10.24% | -1.73% | -34.97% | -33.66% | +114.15% | 12.62B | |
| +0.08% | +0.68% | +1.78% | +31.03% | +22.58% | +31.34% | -12.11% | -40.63% | +155.87% | 11.23B | |
| -0.90% | +2.62% | +0.79% | +40.25% | +16.56% | +39.30% | +12.86% | -42.68% | +167.13% | 11.2B | |
| 0.00% | -6.10% | -21.26% | +6.19% | -11.71% | +73.69% | +535.01% | +266.55% | +2,467.63% | 10.54B | |
| -0.16% | -0.14% | +0.89% | +66.06% | +77.65% | +255.21% | +544.35% | - | - | 10.07B | |
| +2.19% | -4.49% | +26.42% | +25.55% | +29.44% | +22.26% | +31.10% | -60.04% | - | 9.09B | |
| -1.44% | +0.39% | +3.81% | +38.90% | +56.45% | +153.84% | +635.81% | +178.40% | - | 8.79B | |
| -2.83% | -8.45% | -36.71% | -31.23% | -34.56% | +20.31% | +28.11% | +37.58% | +37.18% | 8.6B | |
| +0.03% | -5.37% | -3.36% | -5.05% | +4.44% | +469.11% | +1,952.20% | +31.72% | - | 8.58B | |
| -0.12% | +0.07% | +3.24% | +20.88% | -12.54% | -21.25% | -20.83% | -29.74% | +33.57% | 8.56B | |
| -3.37% | -6.48% | -8.91% | +28.11% | +32.89% | +140.69% | +380.93% | +73.46% | - | 8.51B | |
| Average | -0.90% | -0.51% | -1.26% | +22.87% | +20.05% | +92.35% | +253.24% | +58.86% | +393.08% | 17.43B | |
| Weighted average by Cap. | -0.98% | +0.84% | +0.88% | +23.62% | +24.58% | +89.98% | +187.80% | +81.83% | +411.39% |
- Stock Market
- Stocks
- CLDX Stock
- Sector Celldex Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
